406-420 of 878
Thyroid Cancer and Gender-Affirming Hormone Therapy: Exploring a Potential Link
Project Oncology®Thyroid Cancer and Gender-Affirming Hormone Therapy: Exploring a Potential Link
Nephrotoxicity in the Crosshairs: Optimizing Renal Cancer Care with Kidney Preservation
Project Oncology®Nephrotoxicity in the Crosshairs: Optimizing Renal Cancer Care with Kidney Preservation
Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Project Oncology®Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Project Oncology®Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
Oncology and HematologySunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
Oncology and HematologyTAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
- advertisement
Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
Oncology and HematologyUpdates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
Oncology and HematologyTAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
Oncology and HematologyPhase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
Oncology and HematologyUpdates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
Real-World Sequencing and Survival in Locally Advanced Prostate Cancer
Oncology and HematologyReal-World Sequencing and Survival in Locally Advanced Prostate Cancer
Evolving Trends in Germline Genetic Testing for Prostate Cancer
Oncology and HematologyEvolving Trends in Germline Genetic Testing for Prostate Cancer
- advertisement
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Project Oncology®AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights
Project Oncology®Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights
Alan Bryce, MD
Cannabis Extract and Melanoma: Insights into Cell Death Mechanisms
DermConsultCannabis Extract and Melanoma: Insights into Cell Death Mechanisms
